Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NovoRapid + FIASP
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This combination involves two rapid-acting insulin analogs, **NovoRapid** and **FIASP**, both used to manage blood sugar levels in diabetes. **NovoRapid** contains insulin aspart and is used to treat diabetes mellitus in adults, adolescents, and children. **FIASP** also contains insulin aspart but is formulated to have a faster onset of action compared to NovoRapid. Both are administered subcutaneously and are often used in combination with long-acting insulins.
- Brand names
- FiaspNovoRapid
- Other names
- Faster-acting insulin aspartInsulin aspart
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on NovoRapid + FIASP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovoRapid + FIASP.